Menu Search
Equities

Wuhan YZY Biopharma Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2496:HKG.HS

Wuhan YZY Biopharma Co Ltd

Actions
  • Price (HKD)7.60
  • Today's Change0.000 / 0.00%
  • Shares traded4.00k
  • 1 Year change+3.54%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 02:53 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Wuhan YZY Biopharma Co Ltd is a China-based company mainly engaged in the discovery, development, and commercialization of new innovative drugs in the field of anti-tumor bispecific antibodies. The Company is committed to developing bispecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer, and age-related eye diseases to address the medical needs in oncology and geriatric eye diseases. The Company's core product M701 is a recombinant BsAb that targets human cancer cell surface antigen EpCAM and human T cell surface antigen CD3. The Company's product pipeline also includes Y101D, Y332, Y225, and others.

  • Revenue in HKD (TTM)163.19m
  • Net income in HKD-87.83m
  • Incorporated2010
  • Employees106.00
  • Location
    Wuhan YZY Biopharma Co LtdNo. 666 Gaoxin RoadEast Lake High Tech Development ZoneWUHAN 430075ChinaCHN
  • Phone+86 2 782668988
  • Fax+86 2 768788819
  • Websitehttps://www.yzybio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.